Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551

The nuclear receptor superfamily: the second decade

Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964

Molecular basis of agonism and antagonism in the oestrogen receptor

Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,290

Metastatic Behavior of Breast Cancer Subtypes

Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964

Nuclear Receptor Coregulators: Cellular and Molecular Biology

McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,941

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

† (2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,550

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 129

Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges

Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 117

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88

Accelerating drug development in breast cancer: New frontiers for ER inhibition

Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

Chen, Z., Hu, B., Rej, R. K., Wu, D., Acharyya, R. K., Wang, M., Xu, T., Lü, J., Metwally, H., Wang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01186 · Cited by 54

Development of PROTAC Degrader Drugs for Cancer

Vetma, V., O’Connor, S., & Ciulli, A. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061824-105806 · Cited by 55

Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer

Neupane, N., Bawek, S. J., Gurusinghe, S., Ghaffary, E. M., Mirmosayyeb, O., Thapa, S., Falkson, C. I., O’Regan, R. M., & Dhakal, A. (2024) · Cancers · doi:10.3390/cancers16030619 · Cited by 51

Design, 3D-QSAR, molecular docking, ADMET, molecular dynamics and MM-PBSA simulations for new anti-breast cancer agents

Rhabori, S. E., Alaqarbeh, M., Aissouq, A. E., Bouachrıne, M., Chtita, S., & Khalil, F. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2023.100455 · Cited by 48

Cancer Cell‐Specific Fluorescent Prodrug Delivery Platforms

Ma, S., Kim, J. H., Chen, W., Li, L., Lee, J., Xue, J., Liu, Y., Chen, G., Tang, B., Tao, W., et al. (2023) · Advanced Science · doi:10.1002/advs.202207768 · Cited by 44

Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer

Deng, X., Xie, B., Li, Q., Xiao, Y., Hu, Z., Deng, X., Fang, P., Dong, C., Zhou, H.-B., & Huang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00525 · Cited by 43

Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer

Guglielmi, G., Re, M. D., Gol, L. S., Bengala, C., Danesi, R., & Fogli, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176424 · Cited by 40

Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo

Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39

Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer

Xin, L., Wang, C., Cheng, Y., Wang, H., Guo, X., Deng, X., Deng, X., Xie, B., Hu, H., Min, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00196 · Cited by 38

From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target

Mottamal, M., Kang, B.-R., Peng, X., & Wang, G. (2021) · ACS Omega · doi:10.1021/acsomega.0c06362 · Cited by 37

SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer

Lu, Y., Sheng, X., Liu, C., Liang, Z., Wang, X., Liu, L., Wen, Z., Yang, Z., Du, Q., & Liu, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106731 · Cited by 37

Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview

Bhatia, N. S., Hazra, S., & Thareja, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115422 · Cited by 35

The G Protein-Coupled Estrogen Receptor (GPER): A Critical Therapeutic Target for Cancer

Hall, K. A., & Filardo, E. J. (2023) · Cells · doi:10.3390/cells12202460 · Cited by 30

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Bardia, A., Cortés, J., Hurvitz, S. A., Delaloge, S., Iwata, H., Shao, Z., Kanagavel, D., Cohen, P., Liu, Q., Cartot‐Cotton, S., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083956 · Cited by 31

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

Ma, C. X., Suman, V. J., Sanati, S., Vij, K. R., Anurag, M., Leitch, A. M., Unzeitig, G. W., Hoog, J., Fernández-Martínez, A., Fan, C., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6038 · Cited by 29

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

Wang, Y., Min, J., Deng, X., Feng, T., Hu, H., Guo, X., Cheng, Y., Xie, B., Yang, Y., Chen, C.-C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.005 · Cited by 28

Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment

Xie, B., Xu, B., Xin, L., Wei, Y., Guo, X., & Dong, C. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106590 · Cited by 27

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1796 · Cited by 31

Elacestrant: a new FDA-approved SERD for the treatment of breast cancer

Bhatia, N., & Thareja, S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02045-2 · Cited by 27

Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer

Deng, X., Deng, X., Ning, W., Xin, L., Li, Q., Hu, Z., Xie, B., Liang, K., Min, C., Dong, C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00465 · Cited by 26

Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer

Luo, G., Lin, X., Ren, S., Wu, S., Wang, X., Ma, L., & Xiang, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113870 · Cited by 25

Selective Estrogen Receptor Modulators (SERMs) for the treatment of ER+ breast cancer: An overview

Das, S., Kulkarni, S., Singh, Y., Kumar, P., & Thareja, S. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133853 · Cited by 25

Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities

Yan, S., Ji, J., Zhang, Z., Imam, M., Chen, H., Zhang, D., & Wang, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116615 · Cited by 24

Update on the Role of Neuropeptide Y and Other Related Factors in Breast Cancer and Osteoporosis

Lin, S., Li, Y., Sun, X., Chen, Q., Huang, S., Lin, S., & Cai, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.705499 · Cited by 24

Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha

Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23

Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer

Acharyya, R. K., Rej, R. K., Hu, B., Chen, Z., Wu, D., Lü, J., Metwally, H., McEachern, D., Wang, Y., Jiang, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01521 · Cited by 24

Research Progress on Bioactive Metal Complexes against ER-Positive Advanced Breast Cancer

Liang, Z., Liu, L., Zhou, Y., Liu, W., & Lu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01458 · Cited by 24

Ring systems in medicinal chemistry: A cheminformatics analysis of ring popularity in drug discovery over time

Ertl, P., Altmann, E., & Wilcken, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118178 · Cited by 24

Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

Michmerhuizen, A. R., Lerner, L. M., Pesch, A. M., Ward, C., Schwartz, R. L., Wilder-Romans, K., Liu, M., Nino, C. A., Jungles, K. M., Azaria, R. D., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00397-y · Cited by 22

The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma

Bhutani, K., Vishwakarma, S., Yadav, P., & Yadav, M. K. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106729 · Cited by 20

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2024) · eLife · doi:10.7554/elife.93183.3 · Cited by 18

Integrative strategies in breast cancer therapy: Conventional approaches, emerging advances, and future challenges

Eapen, J. V., George, P. R., Thomas, S., & Antony, J. (2025) · ASPET Discovery · doi:10.1016/j.aspetd.2025.100012 · Cited by 14

Human Estrogen Receptor Alpha Antagonists, Part 3: 3-D Pharmacophore and 3-D QSAR Guided Brefeldin A Hit-to-Lead Optimization toward New Breast Cancer Suppressants

Kurtanović, N., Tomašević, N., Matić, S. L., Proia, E., Sabatino, M., Antonini, L., Mladenović, M. P., & Ragno, R. (2022) · Molecules · doi:10.3390/molecules27092823 · Cited by 14

The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364

Tian, Y., Liu, K., Wu, D., Wu, L., Xu, Q., Wei, W., Li, Z., Du, Q., & Bian, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116275 · Cited by 14

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer

Sharaf, B., Hajahjeh, A., Hani, H. B., & Abdel‐Razeq, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1385577 · Cited by 14

Emerging Roles of RNF168 in Tumor Progression

Xie, T., Qin, H., Yuan, Z., Zhang, Y., Li, X., & Zheng, L. (2023) · Molecules · doi:10.3390/molecules28031417 · Cited by 13

Advancing precision oncology in breast cancer: the FDA approval of elacestrant and guardant 360CDx: a correspondence

Abbasi, H. Q., Adeena, M., Khan, A. M., Shahnoor, S., Oduoye, M. O., & Nafula, W. P. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000334 · Cited by 13

Dual-targeting of the aromatase binding domain of heme and androstenedione by Pt( iv ) prodrugs: a new treatment for postmenopausal breast cancer

Liu, X.-M., Li, Z., He, X.-R., Liu, R.-P., Ma, Z., Qiao, X., Wang, S., & Xu, J. (2022) · Inorganic Chemistry Frontiers · doi:10.1039/d2qi00900e · Cited by 12

The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against Breast Cancer

Chen, F., Wang, Y., Huang, H., Li, W., Ma, J., Yao, D., Tang, Z.-J., Xue, T., Ha, L., Ren, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.651976 · Cited by 12

Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer

Liang, J., Wang, D., Wu, Y., Shi, J., Xie, B., Xiao, R., Ni, J., Wang, C., Dong, C., Shu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00425 · Cited by 12

Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer

Lu, Y., Liu, C., Wang, X., Liu, L., Zhao, Z., Liang, Z., Liu, W., Wen, Z., Du, Q., & Liu, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115324 · Cited by 11

Discovery of highly potent proapoptotic antiestrogens in a series of androst-5,16-dienes D-modified with imidazole-annulated pendants

Birukova, V. E., Scherbakov, A. M., Ilina, A. A., Salnikova, D. I., Andreeva, O. E., Dzichenka, Y. U., Zavarzin, I. V., & Volkova, Y. A. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106309 · Cited by 11

Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants

Kurtanović, N., Stanković, N., Matić, S. L., Mitrović, M. M., Kostić, D. A., Sabatino, M., Antonini, L., Ragno, R., & Mladenović, M. P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113869 · Cited by 11

A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway

Zhou, J., Shen, R., Liu, J., Deng, X., Xin, L., Zhou, H., & Huang, J. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117235 · Cited by 9

Human Estrogen Receptor α Antagonists. Part 1: 3-D QSAR-Driven Rational Design of Innovative Coumarin-Related Antiestrogens as Breast Cancer Suppressants through Structure-Based and Ligand-Based Studies

Mihović, N., Stanković, N., Matić, S. L., Mitrović, M. M., Kostić, D. A., Sabatino, M., Antonini, L., Ragno, R., & Mladenović, M. P. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00530 · Cited by 9

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanismsPreprint

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2023) · eLife · doi:10.7554/elife.93183 · Cited by 9

Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects

Lu, Y., Liang, Z., Liu, L., Zhou, Y., Liu, C., Zhao, Z., Zheng, T., Du, Q., & Liu, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116534 · Cited by 8

The anti-aromatase and anti-estrogenic activity of plant products in the treatment of estrogen receptor-positive breast cancer

Verhoog, N. J. D., & Spies, L.-M. L. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106581 · Cited by 8

Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms

Zhao, S., Gu, J., Tian, Y., Wang, R., & Li, W. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0822 · Cited by 9

Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer

Zhang, D., Lu, Z., He, Y., Leng, X.-Y., Meng, X., Lei, X., Kong, D., Sun, L., Hu, W., & Yang, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02453 · Cited by 7

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

Datta‐Mannan, A., Czeskis, B. A., Shanks, E., Yuen, E., Hall, S. D., Cruz, V. R., & Cassidy, K. C. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1562 · Cited by 6

Post-CDK4/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review

Güren, A. K., Kırcalı, M. F., Köstek, O., & Demircan, N. C. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2593540 · Cited by 6

New Zosteropenillines and Pallidopenillines from the Seagrass-Derived Fungus Penicillium yezoense KMM 4679

Leshchenko, E. V., Chingizova, E. A., Antonov, A. S., Shlyk, N. P., Borkunov, G. V., Berdyshev, D. V., Chausova, V. E., Kirichuk, N. N., Khudyakova, Y. V., Chingizov, A. R., et al. (2024) · Marine Drugs · doi:10.3390/md22070317 · Cited by 6

Pd-Catalyzed Cross-Coupling of Cyclopropanols with 2-Br-p-Quinone Methides/2-Br-Cinnamate Esters Followed by a 1,6- and 1,4-Conjugate Addition Reaction

Mane, B. B., Savekar, A. T., & Waghmode, S. B. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c00092 · Cited by 6

OBHS impairs the viability of breast cancer via decreasing ERα and Atg13

Zhou, J., Shen, R., Zhou, H., & Huang, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.013 · Cited by 6

Exploring TMPRSS2 Drug Target to Combat Influenza and Coronavirus Infection

Baby, K., Vithalkar, M. P., Dastidar, S. G., Mukhopadhyay, C., Hamdy, R. M., Soliman, S. S. M., & Nayak, Y. (2025) · Scientifica · doi:10.1155/sci5/3687892 · Cited by 7

Sustainable ionic liquid design for enhanced solubility and safety of Tamoxifen: A computational exploration

Zheng, D., Jiang, S. H., Qin, S., An, B., & Gao, L. (2025) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2025.102046 · Cited by 5

Structure–Activity Relationships of Triphenylethylene Derivatives and Their Evaluation as Anticancer and Antiviral Agents

Ahmed, N. S., El-Nakib, H. E., Ramsis, M. M., Albably, N. O., Wober, J., Weigand, J. J., Schwedtmann, K., Zierau, O., & Abadi, A. (2023) · ACS Omega · doi:10.1021/acsomega.3c01682 · Cited by 5

Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant

Lu, Y., Zhao, Z., Wang, S., Zheng, T., Chen, X., Liu, L., Zhu, Y., & Liu, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116897 · Cited by 5

Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders

Luo, G., Li, X., Lin, X., Lu, X., Li, Z., & Xiang, H. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106154 · Cited by 5

Cyclopia extracts act as selective estrogen receptor subtype downregulators in estrogen receptor positive breast cancer cell lines: Comparison to standard of care breast cancer endocrine therapies and a selective estrogen receptor agonist and antagonist

Olayoku, F. R., Verhoog, N. J. D., & Louw, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122031 · Cited by 5

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanismsPreprint

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2024) · eLife · doi:10.7554/elife.93183.2 · Cited by 5

Comprehensive analysis of Crotalaria willdenowiana DC.: GC–MS profiling, antioxidant and anticancer activities, molecular docking studies, and in silico ADME profiling

Muthukrishnan, S., Raman, C., Chandrasekaran, G., Soundhirapandi, P., Chinnappan, G., Prakasam, R., Manogar, P., & Pandiyan, J. (2025) · 3 Biotech · doi:10.1007/s13205-025-04409-z · Cited by 4

Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors

Kim, N., & Lukong, K. E. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101134 · Cited by 4

Secondary metabolites of Vietnamese marine fungus Penicillium chermesinum 2104NT-1.3 and their cardioprotective activity

Ngoc, N. T. D., Yurchenko, E. A., Trinh, P. T. H., Menchinskaya, E. S., Trang, V. T. D., Savagina, A. D., Минин, А. С., Thinh, P. D., Khánh, H. H. N., Vân, T. T. T., et al. (2024) · Regional Studies in Marine Science · doi:10.1016/j.rsma.2024.104003 · Cited by 4

Artificial Protein Crosstalk with a Molecule that Exchanges Binding Partners

Suss, O., Halfin, O., Porat, Z., Sirkis, Y. F., Motiei, L., & Margulies, D. H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202312461 · Cited by 4

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanismsPreprint

McSwiggen, D. T., Liu, H., Tan, R., Puig, S. A., Akella, L. B., Berman, R., Bretan, M., Chen, H., Darzacq, X., Ford, K., et al. (2023) · eLife · doi:10.7554/elife.93183.1 · Cited by 4

Artificial Intelligence (AI)-Assisted Treatment of Breast Cancer

Mubasshira, Rahman, M. M., Mondal, J., Parvez, M. M. H., Uddin, M. N., & Akter, L. (2026) · Springer eBooks · doi:10.1007/978-981-95-3682-5_18 · Cited by 5

Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov

Abdullaeva, S., Abdullaeva, P., Gabdrakhimova, R. A., Александровна, Н. К., Евгеньевна, Н. М., Liu, J., MIu, S., Самородов, А. В., Smolyarchuk, Е. А., Sukocheva, O. A., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673345472250301052255 · Cited by 3

A comprehensive overview on mononuclear and multinuclear Ruthenium-based coordination compounds as breast cancer therapeutics

Naseem, M., Siddique, A., Latif, M. S., Alshammari, A. Q., Sheikh, T. A., Alshammari, A. Q., Akhtar, M. N., & Rahman, M. M. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114718 · Cited by 3

Design, synthesis, molecular modeling, and bioactivity evaluation of 1,10-phenanthroline and prodigiosin (Ps) derivatives and their Copper(I) complexes against mTOR and HDAC enzymes as highly potent and effective new anticancer therapeutic drugs

Çetin, M. M., Peng, W., Unruh, D. K., Mayer, M. F., Mechref, Y. S., & Yelekçi, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.980479 · Cited by 3

Structure–Activity Relationship Study of Tris-Benzamides as Estrogen Receptor Coregulator Binding Modulators

Lee, T.-K., Kassees, K., Chen, C., Viswanadhapalli, S., Parra, K., Vadlamudi, R. K., & Ahn, J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00125 · Cited by 3

Docking Study, ADMET Profiling of the Designed 3-Chlorobenzo[b]thiophene-2-Carbonyl Chloride Derivatives: Promising Anti-Breast Cancer Activity

Al-Owaidi, M. F., & Ameri, M. F. A. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00152 · Cited by 3

F-α-DDB-derivative, a novel synthetic of bifendate, plus epirubicin improves antitumor efficacy against triple negative breast cancer without additional cardiotoxicity

Huang, H.-Y., Lin, L. Z. Y., Lu, X., & Jiang, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02545-9 · Cited by 2

Highly potent and selective degrader targeting ERα to improve the treatment outcomes of breast cancer

Bao, X., Yin, X., Xǔ, J., Zhu, Z., Lu, W., Cai, Y., Dai, R., Zheng, Z., Xu, W., Mei, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118199 · Cited by 2

Design, Synthesis, and In Vitro Mitotic Evaluation of 3‐Amino‐Isoquinolinones as Anticancer Agents

Abrams, J. N. (2022) · ChemistrySelect · doi:10.1002/slct.202202861 · Cited by 1

Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer

Dai, R., Bao, X., Liu, C., Yin, X., Zhu, Z., Zheng, Z., Wang, B., Yang, K., Wen, H., Li, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116894 · Cited by 1

Development of Fluorescent Estrogen Receptor Ligands with pH Sensor Functionality

Hirano, T., Yasuda, D., Yamada, T., & Kagechika, H. (2025) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00685 · Cited by 1

Structural evolution progress of orally bioavailable selective estrogen receptor degraders

Zhang, J., Zhang, J., Zhao, Y. Y., Liu, Y., Sun, Y., Lei, H., & Zhai, X. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118288 · Cited by 1

Stability of Steroid Hormone Receptors

Gale-Day, Z. J., & Gestwicki, J. E. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch2

A concise review on breast cancer in pregnancy

Yuvaraj, K., Govindhan, E., Francis Kevin Raj, S., Pavithra, J., & Muralidharan, P. (2023) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2023.8.2.0272 · Cited by 1

Selenium Analogue of LSZ102 as a Highly Potent ER‐α Binder

Paegle, E., & Arsenyan, P. (2023) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202300460

Selenium analogues of rintodestrant (G1T48) as potent estrogen receptor modulators and downregulators

Paegle, E., Dimitrijevs, P., & Arsenyan, P. (2023) · New Journal of Chemistry · doi:10.1039/d3nj01739g

Artificial Protein Crosstalk with a Molecule that Exchanges Binding Partners

Suss, O., Halfin, O., Porat, Z., Sirkis, Y. F., Motiei, L., & Margulies, D. H. (2023) · Angewandte Chemie · doi:10.1002/ange.202312461

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2024) · doi:10.1158/1078-0432.c.7077719

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2024) · doi:10.1158/1078-0432.c.7077719.v1

Design and Structural Investigation of a Series of Prodigiosin and 1,10-Phenanthroline Derivatives as Novel and Highly Potent Anticancer Therapeutic Drugs or Active Pharmaceutical Ingredients

Çetin, M. M., & GÜL, S. B. (2024) · Karadeniz Fen Bilimleri Dergisi · doi:10.31466/kfbd.1423254

Effect of Tasurgratinib as an Orally Available FGFR1–3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER+/HER2− Breast Cancer Preclinical Models

Kawano, S., Fukushima, S., Nishibata, K., Gejima, R., & Miyano, S. W. (2025) · Cancers · doi:10.3390/cancers17071084

The Review of Chemistry, Pharmacological properties and Bio-analytical Methods of Oral selective Estrogen Receptor Degrader: Elacestrant

Vyas, A. J., Ramani, A., & Patel, A. I. (2025) · Asian Journal of Pharmaceutical Analysis · doi:10.52711/2231-5675.2025.00011

Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys

Chen, M., Zhang, H., Chen, S., Liang, P., Wu, Z., Gao, X., Chen, J., Wu, S., Zhang, J., & Tian, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109011

The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases

Tong, J., Wang, P., Ma, S., Li, J., Zhan, Y., Liu, M., Jin, F., Qu, G., Zheng, C., Wang, X., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06132-1

Developing orally active estrogen receptor degraders by conjugation of boronic tamoxifen and cereblon ligands

Peng, X., Hossain, A., Ma, P., Guo, S., Mottamal, M., Zhang, C., 郑时龙, Kang, B., & Wang, G. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118956

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title

Etessami, J. D., Valenza, C., Giachetti, P. P. M. B., Crimini, E., Ferraro, E., Marra, A., Belli, C., Minchella, I., Zagami, P., Curigliano, G., et al. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2678481

Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer

Kuzminac, I. Z., Bekić, S. S., Stevanović, M. Z., Scholda, J., Kopp, F. B., Petri, E. T., Ćelić, A. S., & Sakač, M. N. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70321

Evaluating the investigational drug landscape for ESR1 -mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer

Kroemer, M., Lopez, M., Mansi, L., & Curtit, E. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2686701

NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer

Liang, J., Wu, Y., Yang, L., Xu, B., Wang, D., Shu, H., Dong, C., Li, S., & Zhou, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119113

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

Hernándo, C., Ortega-Morillo, B., Tapia, M., Moragón, S., Martínez, M. T., Eroles, P., Garrido‐Cano, I., Adam‐Artigues, A., Lluch, A. M., Bermejo, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157812 · Cited by 147

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

Downton, T. D., Zhou, F. H., Segara, D., Jeselsohn, R. M., & Lim, E. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s380925 · Cited by 72

Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer

Guglielmi, G., Re, M. D., Gol, L. S., Bengala, C., Danesi, R., & Fogli, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176424 · Cited by 40

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

Ferro, A., Generali, D., Caffo, O., Caldara, A., Lisi, D. D., Dipasquale, M., Lorenzi, M., Monteverdi, S., Fedele, P., & Ciribilli, Y. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.002 · Cited by 9

Selective Estrogen Receptor Degraders (SERDs)

Taylor, M., Kahn, A. M., & Foldi, J. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00563-0 · Cited by 3